Pitcairn CO Astrazeneca PLC Transaction History

Pitcairn CO

$1.67 Billion
Q4 2024

A detailed history of Pitcairn CO transactions in Astrazeneca PLC stock. As of the latest transaction made, Pitcairn CO holds 20,296 shares of AZN stock, worth $1.53 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares

20,296

Previous 23,775 14.63%

Holding current value

$1.53 Million

Previous $1.85 Million 28.24%

% of portfolio

0.08%

Previous 0.11%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 12, 2025	SELL	$63.2 - $79.58 $219,872 - $276,858	-3,479 Reduced 14.63%	20,296 $1.33 Million
Q3 2024 Nov 12, 2024	SELL	$76.67 - $87.62 $64,402 - $73,600	-840 Reduced 3.41%	23,775 $1.85 Million
Q2 2024 Aug 13, 2024	BUY	$66.81 - $80.83 $254,412 - $307,800	3,808 Added 18.3%	24,615 $1.92 Million
Q1 2024 May 13, 2024	BUY	$61.03 - $69.57 $1.27 Million - $1.45 Million	20,807 New	20,807 $1.41 Million
Q4 2023 Jul 09, 2024	SELL	$61.89 - $69.28 $506,507 - $566,987	-8,184 Reduced 39.33%	12,623 $850 Million
Q3 2023 Nov 13, 2023	BUY	$64.85 - $71.7 $97,534 - $107,836	1,504 Added 23.98%	7,777 $526,000
Q2 2023 Aug 11, 2023	BUY	$69.91 - $75.81 $2,446 - $2,653	35 Added 0.56%	6,273 $448,000
Q1 2023 May 05, 2023	BUY	$63.15 - $71.6 $98,261 - $111,409	1,556 Added 33.23%	6,238 $432,000
Q4 2022 Feb 13, 2023	SELL	$54.21 - $70.44 $17,835 - $23,174	-329 Reduced 6.57%	4,682 $317,000
Q3 2022 Nov 10, 2022	BUY	$53.02 - $135.75 $67,759 - $173,488	1,278 Added 34.24%	5,011 $275,000
Q2 2022 Aug 12, 2022	BUY	$59.26 - $71.14 $221,217 - $265,565	3,733 New	3,733 $247,000

Others Institutions Holding AZN

# of Institutions

1,358

Shares Held

512M

Call Options Held

6.08M

Put Options Held

4.44M

View Full List

About ASTRAZENECA PLC

Ticker AZN
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 3,099,020,032
Market Cap $234B
Description
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...

More about AZN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pitcairn CO, based on Form 13F filings with the SEC.

News

Stay updated on Pitcairn CO with notifications on news.

Account